TRDA - NASDAQ
Entrada Therapeutics, Inc.
$6.58
-0.90%Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotEntrada Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Entrada Therapeutics, Inc. Income Statement
TRDA • NASDAQ
| Entrada Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
25.4M | 210.8M | 129M | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(4.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (326K) | (104K) | |
21.3M | 210.8M | 129M | 0.0 | 0.0 | -326K | -104K | |
OPERATING INCOME | |||||||
(177.3M) | (163.8M) | (132.2M) | (97.2M) | (51.1M) | (26.3M) | (11.8M) | |
(41.1M) | (38.5M) | (32.3M) | (30.6M) | (15.2M) | (5.2M) | (3.6M) | |
(142.3M) | (125.3M) | (99.9M) | (66.6M) | (35.9M) | (21.1M) | (8.2M) | |
-156M | 47M | -3.2M | -97.2M | -51.1M | -26.7M | -11.8M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (2.6M) | (0.0) | (0.0) | (0.0) | |
0.0 | 19.5M | 15.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
-6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
13.2M | 19.5M | 15.2M | 2.6M | -31K | 144K | 6.7M | |
-142.8M | 66.5M | 12.1M | -94.6M | -51.2M | -26.5M | -5.1M | |
NET INCOME | |||||||
(924K) | (859K) | (18.7M) | (0.0) | (0.0) | (0.0) | -451K | |
-143.8M | 65.6M | -6.7M | -94.6M | -51.2M | -26.5M | -4.6M |
SEC Filings
TRDA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
S-3 S-3 N/A | November 06, 2025 | November 06, 2025 |
Related Guides
Continue your TRDA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.